ADC	Antibody-drug conjugate
AEs	Adverse events
G3 AE	Grade 3 adverse event
AKT	Protein kinase B
AR	Androgen receptor
ASCO-GU	Genitourinary Cancers Symposium of the American Society of Clinical Oncology
BC	Bladder cancer
NMIBC	Nonmuscle invasive bladder cancer
MIBC	Muscle invasive bladder cancer
BSC	Best supportive care
CPI	Checkpoint inhibition
CR	Complete response
CT	Chemotherapy
D + R/P	Docetaxel + Ramucirumab/Placebo
DoR	Duration of response
EAU	European Association of Urology
ECOG	Eastern Cooperative Oncology Group
EGFR	Epidermal Growth Factor Receptor
EMA	European Medicines Agency
Erd	Erdafitinib
ESMO	European Society for Medical Oncology
ESMO	European Society for Medical Oncology
EV	Enfortumab vedotin
FDA	United States Food and Drug Administration
FGFR	Fibroblast growth factor receptor
FU	Follow up
GA	Genetic alterations
HER2	Human epidermal growth factor receptor 2
i.v.	Intravenously
IgG	Immunglobulin G
ITT	Intention to treat
MAPK	Mitogen-activated protein kinase
MHC	Major histocompatibility complex
mTOR	Mechanistic Target of Rapamycin
M-VAC	Methotrexate, Vinblastine, Adriamycin and Cisplatin
NA	Not available
NR	Not reached
ORR	Objective response rate
OS	Overall survival
PARP	poly(ADP-ribose) polymerase
PD	Progressive disease
PD-(L)1	Programmed cell death (ligand)-1
PFS	Progression free survival
PR	Partial response
PRISMA	Preferred Reporting Items for Systematic Review and meta-analysis Statement
PSN	Peripheral sensory neuropathy
RAM	Ramucirumab
RECIST	Response evaluation criteria in solid tumors
RTK	Receptor tyrosine kinases
SG	Sacituzumab govitecan
SRM	Selected regimen
TCGA	The Cancer Genome Atlas
TKI	Tyrosine kinase inhibitor
(m)UC	(Metastatic) urothelial carcinoma
UTI	Urinary tract infection
VEGF	Vascular endothelial growth factor
WBC	White blood cell